FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
FDA recently approved the first gene therapy for Duchenne Muscular Dystrophy (DMD) for pediatric patients between 4-5 years of age. The drug, Elevidys, made by Sarepta Therapeutics is a adeno-associated virus vector-based gene therapy targeting the DMD gene.
Search our Directory
AABRM Members are not only experts in regenerative medicine but offer a wide range of related products, services and related-procedures in that field. Search our extensive Member Directory to find a Member near you.Member Directory